This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / MiNK Therapeutics agenT-797 Phase II Data
Tech clinical trial

MiNK Therapeutics agenT-797 Phase II Data

Analysis based on 12 articles · First reported Apr 03, 2026 · Last updated Apr 17, 2026

Sentiment
60
Attention
4
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase II clinical trial data for MiNK Therapeutics' agenT-797 could lead to increased investor confidence and a potential rise in MiNK Therapeutics' stock price. This development is significant for the biotechnology and pharmaceutical industries, particularly in the oncology sector, as it offers a new potential treatment strategy for a challenging cancer.

Biotechnology Pharmaceuticals
Event Summary

MiNK Therapeutics announced positive data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center. The trial evaluated agenT-797, MiNK Therapeutics' allo-iNKT cell therapy, in combination with botensilimab and balstilimab, ramucirumab, and paclitaxel for patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The study achieved a 77% disease control rate and showed long-term survival beyond 20 months in a subset of patients, with meaningful improvements in progression-free survival and overall survival in patients who received an induction strategy. Jennifer Buell, President and CEO of MiNK Therapeutics, highlighted the potential of agenT-797 as an immune orchestrator. The data will be presented by Samuel L. Cytryn at the American Association for Cancer Research Annual Meeting.

Entities Involved
per
Jennifer Buell
Jennifer Buell, President and CEO of MiNK Therapeutics, provided commentary on the positive trial results and the potential of agenT-797.
Importance 50.0 Sentiment 30.0
per
Samuel L. Cytryn
Samuel L. Cytryn, a Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center, is the presenter of the Phase II study data at the AACR Annual Meeting.
Importance 40.0 Sentiment 20.0
ngo
American Association for Cancer Research
The American Association for Cancer Research is hosting its Annual Meeting where the Phase II trial data for agenT-797 will be presented.
Importance 30.0 Sentiment 10.0
stock
MiNK Therapeutics
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.